Futura Medical (LON:FUM) Announces Quarterly Earnings Results

Futura Medical (LON:FUM) announced its quarterly earnings data on Wednesday. The company reported GBX (2.78) earnings per share (EPS) for the quarter, Digital Look Earnings reports. The firm had revenue of GBX 170 million during the quarter. Futura Medical had a negative return on equity of 104.83% and a negative net margin of 79.41%.

Futura Medical Price Performance

Shares of FUM stock traded down GBX 0.41 during mid-day trading on Wednesday, hitting GBX 0.89. The stock had a trading volume of 50,766,512 shares, compared to its average volume of 6,546,674. Futura Medical has a 12-month low of GBX 0.75 and a 12-month high of GBX 15. The firm has a market capitalization of £5.17 million, a P/E ratio of -0.43 and a beta of 0.19. The firm’s 50-day moving average is GBX 1.21 and its two-hundred day moving average is GBX 1.43.

About Futura Medical

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon® and products WSD4000 and Eroxon® Intense. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.

Sexual health issues are prevalent in both men and women. ED impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40.